FDA Advisers Recommend Approval Of Novavax COVID-19 Vaccine

June 10, 2022 2:12 pm Published by

Here in the United States our health agencies such as the Food and Drug Administration (FDA) and Centers for Disease Control (CDC) have already approved three COVID-19 vaccines. The Johnson and Johnson vaccine, which requires just one dose, and the Moderna and Pfizer vaccines which is a two shot series have been in circulation in the U.S. for over a year now. Now there may be a fourth vaccine coming from Novavax.

This week, advisors at the FDA recommended that the FDA and CDC allow the Novavax to be given Emergency Use Authorization (EUA) for members of the U.S. population. The vaccine, which has received EUA in other countries around the world, is now being considered as an additional tool for health officials in the U.S. to battle COVID-19 as it continues to spread throughout the country.

Currently 67% of the U.S. population is fully vaccinated from the COVID-19 virus, but when a booster shot is taken into account that number drops significantly. It is also troubling that there is a large percent of the population that has decided to not get vaccinated against the virus at all.

Health officials are hoping that the Novavax vaccine, which was researched and developed in a more traditional way, may convince those who have yet to get vaccinated to go ahead and receive their two doses of this new vaccine. Some believe that hesitancy among the U.S. public will wane when they discover that this drug was developed with traditional processes.

The next step for EUA is for the vaccine to be reviewed by the whole FDA and if it accepts the recommendation of the smaller group of advisors, it will be passed along to the CDC who will have the final word on whether or not the drug will be approved. If approved, the company has said it has millions of doses ready to be shipped to the United States in short order.